Interleukin-lβ converting enzyme (ICE); Caspase-1

人IL-1β和Ac-YVAD-CHO抑制剂的IC50值分别为0.7 μM和2.5 μM[1]。 Ac-YVAD-CHO (0.01-100 μM) 降低经脂毒性休克处理的豚鼠腹腔液中的 IL。 Ac-YVAD-CHO (15.6 μM) 降低胸腺细胞 NO 诱导 [3]。在用 SNAP 处理的胸腺细胞中，Ac-YVAD-CHO（15.6 μM，12 小时）可防止 NO 诱导 [3]。

---

泛胱天蛋白酶抑制剂ZVAD-fmk和胱天蛋白酶-1抑制剂Ac-YVAD-CHO均以剂量依赖的方式抑制NO诱导的胸腺细胞凋亡，而胱天蛋白酶-3抑制剂Ac-DEVD-CHO即使在高达500微M的浓度下也几乎没有效果。在用NO供体S-亚硝基-N-乙酰青霉胺（SNAP）处理后，ZVAD-fmk和Ac-YVAD-CHO在添加12小时时能够抑制细胞凋亡，而不是16小时。Caspase-1活性在4小时和8小时上调，24小时恢复到基线水平；未检测到caspase-3活性。SNAP处理的胸腺细胞胞浆组分切割胱天蛋白酶激活的脱氧核糖核酸酶抑制剂。Ac-YVAD-cho完全阻断了这种切割，但Ac-DEVD-cho或DEVD-fmk没有阻断。SNAP处理后8小时和12小时，胸腺细胞中的聚ADP核糖聚合酶（PARP）也被切割；向培养物中添加Ac-YVAD-cho可阻断PARP切割。此外，SNAP诱导野生型小鼠44%的胸腺细胞凋亡；caspase-1敲除小鼠的胸腺细胞对NO诱导的凋亡更具抵抗力。这些数据表明，NO通过半胱天冬酶-1依赖而非半胱天冬蛋白酶-3依赖的途径诱导胸腺细胞凋亡。单独使用Caspase-1可以切割Caspase激活的脱氧核糖核酸酶抑制剂，导致DNA断裂，从而为NO诱导的胸腺细胞凋亡提供了一条新途径[3]。

暴露于痤疮丙酸杆菌的小鼠静脉中的 IL-1β 水平被Ac-YVAD-CHO（30 mg/kg；腹腔注射；6 小时）抑制[1]。注射后 30 和 30 天，Ac-YVAD-CHO（10 和 50 mg/kg；腹腔注射；1 小时）和 Ac-YVAD-CHO（2-8 μg，纹状体输注）迅速从循环中去除。

---

白细胞介素-1β转化酶（ICE）的一种强效、可逆的四肽抑制剂L-709049已被证明可以抑制成熟IL-1β的体外产生。我们现在报告说，这种抑制剂还有效地抑制了内毒素休克小鼠模型中成熟IL-1β的产生。腹腔注射L-709049以剂量相关方式降低了用LPS治疗的小鼠血浆和腹膜液中IL-1β的升高（ED50=2+/-0.9mg/kg）。LPS诱导的这些小鼠IL-1α和IL-6的升高不受影响，表明抑制剂特异性影响IL-1β的产生。血浆和腹腔液的免疫印迹分析表明，L-709049抑制了体内成熟IL-1β生成的形成。当小鼠血液在体外与LPS一起孵育时，IL-1β释放到血浆中。该测定用于测定小鼠服用ICE抑制剂后血液中ICE抑制剂的体外活性。小鼠腹腔注射10mg/kg L-709049 15分钟后获得的血液产生的IL-1β比对照血液少80%，注射该抑制剂30分钟后血液中IL-1β的产生恢复到对照水平。此外，从这些动物获得的血浆防止ICE切割合成底物的能力在ip施用50mg/kg抑制剂后1小时内消失。[1]

---

用Ac-YVAD-CHO预处理可抑制QA诱导的核小体间DNA断裂。Ac-YVAD-CHO抑制QA诱导的胱天蛋白酶-1活性和p53蛋白水平的增加，但对QA诱导的IκB-α降解、NF-κB或AP-1活化没有影响。 结论： Caspase-1参与QA诱导的p53上调，但不参与IκB-α的降解。抑制胱天蛋白酶-1可减弱QA诱导的大鼠纹状体细胞凋亡[2]。

在无细胞重建系统中诱导细胞凋亡[3]
该程序如前所述进行。反应混合物含有40μl S-100组分（约5mg/ml）；10μl核溶液（约1×106个核）；以及终浓度为80μl缓冲液F（10 mM HEPES（pH 7.4）、40 mM b-甘油磷酸、50 mM NaCl、2 mM MgCl2、4 mM EGTA、2 mM ATP、10 mM磷酸肌酸酐、50μg/ml肌酸酐激酶和0.2 mg/ml BSA）中的400 ng预处理的rh-天冬氨酸酶-1或rh-天冬酶-3、15.6μMAc-YVAD-CHO或15.6μM Ac-DEVD-CHO。混合物在37°C下孵育140分钟，偶尔混合。然后将反应溶液与500μl缓冲液G（50 mM Tris-HCl（pH 7.4）、1 mM EDTA、1%SDS和0.2 mg/ml蛋白酶K）混合，并在37°C下孵育1小时。用苯酚/氯仿提取溶液。如前所述进行DNA分离和电泳。

蛋白质印迹分析 [3]
细胞类型： SNAP 处理的胸腺细胞
测试浓度： 15.6 μM
孵育时间： > 12 小时
实验结果：PARP 裂解减弱。

Animal/Disease Models: Quinolinic acid-treated rats [2]
Doses: 2-8 μg
Route of Administration: intrastriatal infusion.
Experimental Results: Attenuated quinolinic acid (QA)-induced increase in p53 and apoptosis in rat striatum. Inhibition of QA-induced increases in caspase-1 activity and p53 protein levels had no effect on QA-induced IκB-α degradation, NF-κB or AP-1 activation.

---

Rats were pre-treated with intrastriatal infusion of Ac-YVAD-CHO (2-8 μg) before intrastriatal injection of QA (60 nmol). Striatal total proteins, genomic DNA, and nuclear proteins were isolated. The effects of Ac-YVAD-CHO on QA-induced caspase-1 activity, Internucleosomal DNA fragmentation, IκB-α degradation, NF-κB, and AP-1 activation, and increases in p53 protein levels were measured with enzyme assays, agarose gel electrophoresis, electrophoresis mobility shift assays, and Western blot analysis.[2]

---

Stereotaxic drug administration Sprague-Dawley rats (300–350 g) were used. Rats were anesthetized with pentobarbital sodium (50 mg/kg). Stereotaxic drug administration was performed using a Kopf stereotaxic apparatus as described by Qin et al. To study the effects of a caspase-1 inhibitor on QA-induced internucleosomal DNA fragmentation, rats were either pretreated with an intrastriatal infusion of Ac-YVAD-CHO (2–8 µg) or Me2SO (2 µL) 10 min before instrastriatal injection of QA (60 nmol) and then killed 24 h after QA administration, or pre-treated with intrastriatal infusion of Ac-YVAD-CHO (4 µg) 10 min before instrastriatal injection of QA (60 nmol) and killed 12, 24, or 48 h after QA administration. Striatal genomic DNA was isolated and electrophoresed on a 2% agarose gel. To study the effect of a caspase-1 inhibitor on QA-induced increases in caspase-1 activity, rats were pre-treated with an intrastriatal infusion of Ac-YVAD-CHO (4 µg) or Me2SO (2 µL ) 10 min before intrastriatal injection of QA (60 nmol) and then killed 12 h after QA treatment. Striatal homogenates were used for assay of caspase-1 activity. To study the effect of a caspase-1 inhibitor on QA-induced increases in p53 proteins and NF-κB and AP-1 binding activities, rats were pre-treated with intrastriatal infusion of Ac-YVAD-CHO (4 µg) or Me2SO (2 µL) 10 min before intrastriatal injection of QA (60 nmol) and then killed 24 h after QA treatment. Total striatal proteins were extracted for Western blot analysis. Other animals were killed 12 h after QA treatment and nuclear proteins were isolated from the striatum for an electrophoresis mobility shift assay.

[1]. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. J Interferon Cytokine Res. 1995;15(3):243-248.

[2]. Caspase-1 inhibitor Ac-YVAD-CHO attenuates quinolinic acid-induced increases in p53 and apoptosis in rat striatum. Acta Pharmacol Sin. 2005 Feb;26(2):150-4.

[3]. Nitric oxide induces thymocyte apoptosis via a caspase-1-dependent mechanism. J Immunol. 2000 Aug 1;165(3):1252-8.

In conclusion, we found that the caspase-1 inhibitor AcYVAD-CHO inhibited the QA-induced increase in p53 protein levels and internucleosomal DNA fragmentation, but had no effect on QA-induced IκB-α degradation and NF-κB activation. These results suggest that caspase-1 plays an important role in QA-induced p53 induction and apoptosis, but caspase-1 does not contribute to the QA-induced degradation of IκB-α or NF-κB activation. [2]

---

Caspase-1 activity was four times higher in SNAP-treated thymocytes at 8 and 12 h compared with untreated cells. Caspase-1 activity decreased thereafter. Both ZVAD-fmk and Ac-YVAD-cho inhibited NO-induced apoptosis when added up to 12 h after SNAP treatment. The inhibitory effect was lost after 16 h. PARP cleavage takes place after the amino acid sequence Ac-DEVD-cho. Originally this activity was attributed to caspase-3, but caspases-2,-4,-6,-7,-8, and -10, when added at high concentrations, can also cleave PARP. Because the rate of spontaneous apoptosis in our thymocyte cultures was 20%, it is not surprising that some (mild) PARP cleavage was found in untreated thymocytes. However, there was greater PARP cleavage after SNAP treatment, and it was blocked by Ac-YVAD-cho, even when added 8 h after SNAP treatment. Because neither caspase-3 nor caspase-9 was significantly activated during SNAP treatment, caspase-1 (or other caspases) was likely responsible for the cleavage of PARP in our cultures. [3]

C23H32N4O8

492.52218

492.222

C, 56.09; H, 6.55; N, 11.38; O, 25.99

143313-51-3

Ac-YVAD-CHO acetate

5311139

Ac-Tyr-Val-Ala-Asp-al; N-acetyl-L-tyrosyl-L-valyl-L-alanyl-L-aspart-1-al

Ac-YVAD-CHO; YVAD

White to off-white solid powder

1.3±0.1 g/cm3

937.7±65.0 °C at 760 mmHg

520.9±34.3 °C

0.0±0.3 mmHg at 25°C

1.552

0.79

191

6

8

13

35

780

4

C[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)C

LPIARALSGDVZEP-SJVNDZIOSA-N

InChI=1S/C23H32N4O8/c1-12(2)20(23(35)24-13(3)21(33)26-16(11-28)10-19(31)32)27-22(34)18(25-14(4)29)9-15-5-7-17(30)8-6-15/h5-8,11-13,16,18,20,30H,9-10H2,1-4H3,(H,24,35)(H,25,29)(H,26,33)(H,27,34)(H,31,32)/t13-,16-,18-,20-/m0/s1

(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid

Ac-Yvad-cho; L-709049; Ac-Tyr-Val-Ala-Asp-aldehyde (pseudo acid); NVF6UYC3CM; ...; Caspase-1 Inhibitor I - CAS 143313-51-3;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。